Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group

The New England Journal of Medicine
M M KoopmanMartin H Prins

Abstract

An intravenous course of standard (unfractionated) heparin with the dose adjusted to prolong the activated partial-thromboplastin time to a desired length is the standard initial in-hospital treatment for patients with deep-vein thrombosis, but fixed-dose subcutaneous low-molecular-weight heparin appears to be as effective and safe. Because the latter treatment can be given on an outpatient basis, we compared the two treatments in symptomatic outpatients with proximal-vein thrombosis but no signs of pulmonary embolism. We randomly assigned patients to adjusted-dose intravenous standard heparin administered in the hospital (198 patients) or fixed-dose subcutaneous low-molecular-weight heparin administered at home, when feasible (202 patients). We compared the treatments with respect to recurrent venous thromboembolism, major bleeding, quality of life, and costs. Seventeen of the 198 patients who received standard heparin (8.6 percent) and 14 of the 202 patients who received low-molecular-weight heparin (6.9 percent) had recurrent thromboembolism (difference, 1.7 percentage points; 95 percent confidence interval, -3.6 to 6.9). Major bleeding occurred in four patients assigned to standard heparin (2.0 percent) and one patient assi...Continue Reading

References

Nov 19, 1992·The New England Journal of Medicine·D P BrandjesJ W ten Cate
Sep 1, 1992·Thrombosis Research·M UdvardyK Rak
Oct 15, 1992·The New England Journal of Medicine·P PrandoniJ W ten Cate
Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C HürnyH J Senn
Jan 1, 1991·International Journal of Technology Assessment in Health Care·M F Drummond, L Davies
Jun 27, 1991·The New England Journal of Medicine·J Hirsh
May 30, 1991·The New England Journal of Medicine·J Hirsh
Jul 6, 1995·The New England Journal of Medicine·S C CannegieterE Briët
Mar 27, 1995·Archives of Internal Medicine·A W LensingJ Hirsh
Feb 24, 1994·The New England Journal of Medicine·P J Svensson, B Dahlbäck

❮ Previous
Next ❯

Citations

Feb 11, 2005·Microsurgery·Nilgün Markal ErtaşMaria Siemionow
Dec 1, 1996·Pharmacy World & Science : PWS·H ten CateJ W ten Cate
Feb 13, 1999·Comprehensive Therapy·M D Freedman, M Young
Jun 13, 2006·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·Philippe de MoerlooseSerge Motte
Nov 15, 2002·International Journal of Hematology·Walter Ageno
Sep 17, 2009·Der Orthopäde·L-C Linke
Mar 6, 2007·Journal of Thrombosis and Thrombolysis·Thomas M HyersUNKNOWN INNOVATE Investigators
Nov 11, 2009·Journal of Thrombosis and Thrombolysis·Wendy Lim
Jun 20, 2008·Internal and Emergency Medicine·Wendy Lim
Apr 7, 2004·Current Treatment Options in Cardiovascular Medicine·Wee Shian Chan
Nov 30, 2000·Current Treatment Options in Cardiovascular Medicine·H Al-ZahraniJ I Weitz
Jun 29, 2013·Advances in Therapy·Thomas Vanassche, Peter Verhamme
May 14, 2005·Current Surgery·Eric J HanlyElizabeth A Mittendorf
Sep 20, 1997·The American Journal of Cardiology·A G Turpie
Jun 23, 1999·The American Journal of Medicine·A S Dunn, B Coller
Nov 24, 1999·The American Journal of Medicine·R H WhiteP S Romano
Feb 25, 2005·Gastrointestinal Endoscopy·Marc J ZuckermanUNKNOWN Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy
Dec 22, 1999·Thrombosis and Haemostasis·C Kearon
Aug 23, 2001·Thrombosis Research·A Y Lee
Apr 18, 2002·Thrombosis Research·Hugo A GuglielmoneJosé L Cabrera
Apr 8, 2003·Thrombosis Research·Walter AgenoAchille Venco
Feb 11, 2000·Thrombosis Research·W Ageno
Feb 16, 1999·Lancet·A W LensingH R Büller
Aug 5, 2000·Pharmacology & Therapeutics·R I Shulman
Aug 26, 1998·International Journal of Cardiology·G Agnelli, F Sonaglia
Apr 15, 1999·Resuscitation·R de Vos
Jul 31, 2003·Cancer Treatment Reviews·Mark N Levine
Jan 5, 2002·Emergency Medicine Clinics of North America·D F Brown
Jul 1, 1997·The Journal of Emergency Medicine·G D InnesA Holmes
Aug 30, 2001·Critical Care Clinics·M T DeSancho, J H Rand
Apr 30, 2003·European Journal of Internal Medicine·Albert Y.H. LimChristopher D. Fegan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.